Dissecting the impact of bromodomain inhibitors on the Interferon Regulatory Factor 4-MYC oncogenic axis in multiple myeloma (2022)
Attributed to:
Therapeutic targeting of refractory/relapsed diffuse large B-cell lymphoma through systems biology
funded by
FLF
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1002/hon.3016
PubMed Identifier: 35544413
Publication URI: http://europepmc.org/abstract/MED/35544413
Type: Journal Article/Review
Parent Publication: Hematological Oncology
Issue: 3
ISSN: 0278-0232